{"id":"NCT02144077","sponsor":"Biofrontera Bioscience GmbH","briefTitle":"Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy","officialTitle":"A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01-28","primaryCompletion":"2015-11-17","completion":"2020-09-09","firstPosted":"2014-05-21","resultsPosted":"2019-03-11","lastUpdate":"2022-11-03"},"enrollment":281,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Basal Cell Carcinoma (BCC)"],"interventions":[{"type":"DRUG","name":"BF-200 ALA","otherNames":["Ameluz"]},{"type":"DRUG","name":"methyl-aminolevulinate","otherNames":["Metvix / Metvixia"]}],"arms":[{"label":"BF-200 ALA","type":"ACTIVE_COMPARATOR"},{"label":"methyl-aminolevulinate","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of this study is to test the effectiveness and safety of the medicine Ameluz® (5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with photodynamic therapy (PDT), to treat thin, non-aggressive BCC (basal cell carcinoma).","primaryOutcome":{"measure":"Overall Patient Complete Response Rate Assessed 12 Weeks After the Last PDT","timeFrame":"12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).","effectByArm":[{"arm":"BF-200 ALA","deltaMin":93.4,"sd":null},{"arm":"Methyl-aminolevulinate","deltaMin":91.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":17},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":["29432644"],"seeAlso":["http://www.ncbi.nlm.nih.gov/pubmed/29432644"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":138},"commonTop":["Application site pain","Application site erythema","Application site pruritus","Application site oedema","Application site paraesthesia"]}}